- Home
- ICON vs PCSA Comparison
ICON vs PCSA Comparison
Compare ICON & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- PCSA
- Stock Information
- Founded
- ICON 2023
- PCSA 2011
- Country
- ICON Greece
- PCSA United States
- Employees
- ICON N/A
- PCSA 13
- Industry
- ICON
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- PCSA Health Care
- Exchange
- ICON Nasdaq
- PCSA Nasdaq
- Market Cap
- ICON 3.9M
- PCSA 3.3M
- IPO Year
- ICON 2024
- PCSA N/A
- Fundamental
- Price
- ICON $2.31
- PCSA $0.22
- Analyst Decision
- ICON Strong Buy
- PCSA Strong Buy
- Analyst Count
- ICON 1
- PCSA 1
- Target Price
- ICON $4.50
- PCSA $6.00
- AVG Volume (30 Days)
- ICON 3.3M
- PCSA 46.5M
- Earning Date
- ICON 04-23-2025
- PCSA 08-12-2025
- Dividend Yield
- ICON 100.00%
- PCSA N/A
- EPS Growth
- ICON N/A
- PCSA N/A
- EPS
- ICON N/A
- PCSA N/A
- Revenue
- ICON $5,309,000.00
- PCSA N/A
- Revenue This Year
- ICON $51.78
- PCSA N/A
- Revenue Next Year
- ICON $51.90
- PCSA N/A
- P/E Ratio
- ICON N/A
- PCSA N/A
- Revenue Growth
- ICON 18.61
- PCSA N/A
- 52 Week Low
- ICON $1.60
- PCSA $0.15
- 52 Week High
- ICON $154.00
- PCSA $3.10
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- PCSA 44.28
- Support Level
- ICON N/A
- PCSA $0.20
- Resistance Level
- ICON N/A
- PCSA $0.33
- Average True Range (ATR)
- ICON 0.00
- PCSA 0.09
- MACD
- ICON 0.00
- PCSA -0.01
- Stochastic Oscillator
- ICON 0.00
- PCSA 6.53
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).